[go: up one dir, main page]

EP3038612B1 - Cyclische vinylogenamide als bromdomänenhemmer - Google Patents

Cyclische vinylogenamide als bromdomänenhemmer Download PDF

Info

Publication number
EP3038612B1
EP3038612B1 EP14839424.0A EP14839424A EP3038612B1 EP 3038612 B1 EP3038612 B1 EP 3038612B1 EP 14839424 A EP14839424 A EP 14839424A EP 3038612 B1 EP3038612 B1 EP 3038612B1
Authority
EP
European Patent Office
Prior art keywords
amino
methyl
oxocyclopent
nao
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP14839424.0A
Other languages
English (en)
French (fr)
Other versions
EP3038612A1 (de
EP3038612A4 (de
Inventor
Ming-Ming Zhou
Michael Ohlmeyer
Adam Vincek
Nilesh ZAWARE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icahn School of Medicine at Mount Sinai
Original Assignee
Icahn School of Medicine at Mount Sinai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icahn School of Medicine at Mount Sinai filed Critical Icahn School of Medicine at Mount Sinai
Publication of EP3038612A1 publication Critical patent/EP3038612A1/de
Publication of EP3038612A4 publication Critical patent/EP3038612A4/de
Application granted granted Critical
Publication of EP3038612B1 publication Critical patent/EP3038612B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/20—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C229/48—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms of the same non-condensed ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/56—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in ortho-position
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/60—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in meta- or para- positions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/68—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings being part of the same condensed ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/40—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C07D215/06—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/21—Radicals derived from sulfur analogues of carbonic acid

Definitions

  • the present application relates generally to compositions for treating diseases that arise from inappropriate activity of proteins containing an acetyl-lysine.
  • the compositions comprise a genus of cyclic vinylogous amides that are inhibitors of bromodomain.
  • BRD4 is a member of the bromodomains and extra terminal domain (BET) family of proteins that recognize acetylated chromatin structures through their bromodomains and act as transcriptional activators.
  • Brd4 functions as an associated factor and positive regulator of P-TEFb, a Cdk9-cyclin T heterodimer that stimulates transcriptional elongation by RNA polymerase II.
  • Bromodomain-containing protein 4 (BRD4) contains two tandem bromodomains (BrD1 and BrD2) that bind preferentially to acetylated lysine residues found in histones and nonhistone proteins. This molecular recognition allows Brd4 to associate with acetylated chromatin throughout the cell cycle and regulates transcription at targeted loci.
  • AML Acute myeloid leukemia
  • NP- ⁇ B-mediated inflammation is the major pathology in chronic kidney diseases, including HIV-associated nephropathy that ultimately progresses to end stage renal disease. HIV infection in the kidney induces NF- ⁇ B activation, leading to the production of proinflammatory chemokines, cytokines, and adhesion molecules.
  • NF- ⁇ B activation leading to the production of proinflammatory chemokines, cytokines, and adhesion molecules.
  • the invention relates to a compound of formula I or a pharmaceutically acceptable salt thereof wherein:
  • the invention in a second aspect, relates to pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a compound described herein.
  • the invention in a third aspect, relates to a compound of general formula I for use in for use in treating a disease or disorder selected from the group consisting of chronic inflammation, autoimmune disease, and cancer.
  • the use comprises administering to a patient in need thereof a therapeutically effective amount of a compound described herein.
  • the invention further relates to a compound of general formula I for use in treating a disease or disorder as detailed above, wherein the treatment of a disease or a disorder further comprises administering an additional therapeutic agent
  • the invention in a fourth aspect, relates to a compound of general formula I for in vitro use in inhibiting bromodomain in a cell.
  • the method comprises contacting the cell with an inhibitory amount of a compound described herein.
  • the invention relates to compounds having general formula I :
  • Cy is selected from the group consisting of phenyl, naphthyl, indole, quinoline, isoquinoline, pyridine, and benzimidazolyl. In some embodiments, Cy is phenyl or naphthyl, or pyridinyl. When Cy is phenyl, the compounds have the general formula:
  • U is -CH 2 CH 2 -
  • the vinylogous amide is an N-substituted 3-aminocyclohex-2-enone.
  • U is -CH 2 -
  • the vinylogous amide is an N-substituted 3-aminocyclopent-2-enone.
  • the cycloalkenone is substituted at the 2-position with a substituent R 1 .
  • R 1 is nitrile.
  • R 1 is substituted or unsubstituted (C 1 -C 10 )alkyl.
  • R 1 is preferably (C 1 -C 6 )alkyl, most commonly methyl.
  • R 11 and R 12 are independently selected from the group consisting of H, (C 1 -C 10 )alkyl, (C 1 -C 10 )perfluoroalkyl, halogen, hydroxy, (C 1 -C 10 )alkoxy, amino, (C 1 -C 10 )alkylamino, (C 1 -C 10 )acylamino, aryl, heteroaryl, aminocarbonyl, carboxyl, and (C 1 -C 10 )alkoxycarbonyl.
  • at least one of R 11 and R 12 is hydrogen.
  • R 11 and R 12 may form a 5, 6, or 7-membered carbocycle or heterocycle.
  • the carbocycle or heterocycle may be optionally substituted with R 2 .
  • R 2 is selected from halogen, (C 1 -C 4 )alkyl, halo(C 1 -C 4 )alkyl, hydroxy, (C 1 -C 4 )alkoxy, halo(C 1 -C 4 )alkoxy, carboxy, amino, (C 1 -C 4 )alkylamino or di(C 1 -C 4 )alkylamino.
  • Y is a sulfonamide, such as In some embodiments Y is a urea of the formula or In some embodiments Y is a carboxamide, such as In such compounds, L may be a direct bond, L' may be a direct bond or both L and L' may be direct bonds. In one embodiment, Y is and both L and L' are direct bonds, i.e. Y is In some embodiments, Y is In these compounds, the wavy line indicates that a particular stereochemical configuration is not designated; thus a carbon-carbon double bond depicted arbitrarily herein as trans may be cis, trans , or a mixture of the two in any proportion.
  • R 21 is hydrogen. In some of these embodiments, R 21 is (C 1 -C 4 )alkyl, particularly methyl. In some embodiments, Y is In some of these embodiments, R 21 is (C 1 -C 4 )alkyl. In other embodiments, R 21 is hydrogen. In some embodiments, L is a direct bond and R 21 is hydrogen. In other embodiments, Y may be a 5-membered heterocycle selected from: and 1,2,3-triazoles are preferred. When Y is a substituted 5-membered heterocycle, L may be -(CR 3 R 4 ) m , particularly -CH 2 -.
  • R 10 may be cyclohexyl, cyclopentyl, phenyl, naphthyl, thiophenyl, pyrrolyl, pyridinyl, or pyrimidinyl, each optionally substituted with R 7 and/or R 8 . Cyclohexyl, phenyl and naphthyl are preferred.
  • R 10 When R 10 is phenyl, in some embodiments it may be only singly substituted with R 7 , and, in those embodiments, the structure may be represented: In these compounds, R 7 may be halogen, (C 1 -C 4 )alkyl, halo(C 1 -C 4 )alkyl, (C 1 -C 4 )alkoxy, halo(C 1 -C 4 )alkoxy or aminocarbonyl. Fluoro, chloro, methyl and methoxy are preferred. In some embodiments, R 10 is phenyl subsituted with both R 7 and R 8 .
  • R 7 and R 8 may each independently be halogen, (C 1 -C 4 )alkyl, halo(C 1 -C 4 )alkyl, (C 1 -C 4 )alkoxy, halo(C 1 -C 4 )alkoxy or aminocarbonyl.
  • R 8 is fluoro.
  • the invention in a second aspect, relates to pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a compound described herein.
  • the invention relates to a compound described herein for use in therapy.
  • the use comprises administering to a patient in need thereof a therapeutically effective amount of a compound described herein.
  • the disease or disorder is chronic inflammation.
  • the disease or disorder is autoimmune disease.
  • the disease or disorder is cancer.
  • an additional therapeutic agent may be administered.
  • the invention in a fourth aspect, relates to a compound described herein for in vitro use in inhibiting bromodomain in a cell.
  • the method comprises contacting the cell with an inhibitory amount of a compound described herein.
  • C 1 to C 10 hydrocarbon includes alkyl, cycloalkyl, polycycloalkyl, alkenyl, alkynyl, aryl and combinations thereof. Examples include benzyl, phenethyl, cyclohexylmethyl, adamantyl, camphoryl and naphthylethyl. Hydrocarbyl refers to any substituent comprised of hydrogen and carbon as the only elemental constituents.
  • Aliphatic hydrocarbons are hydrocarbons that are not aromatic; they may be saturated or unsaturated, cyclic, linear or branched. Examples of aliphatic hydrocarbons include isopropyl, 2-butenyl, 2-butynyl, cyclopentyl, norbornyl, etc.
  • Aromatic hydrocarbons include benzene (phenyl), naphthalene (naphthyl), anthracene, etc.
  • alkyl (or alkylene) is intended to include linear or branched saturated hydrocarbon structures and combinations thereof.
  • Alkyl refers to alkyl groups from 1 to 20 carbon atoms, preferably 1 to 10 carbon atoms, more preferably 1 to 6 carbon atoms. Examples of alkyl groups include methyl, ethyl, propyl, isopropyl, n-butyl, s-butyl, t-butyl and the like.
  • Cycloalkyl is a subset of hydrocarbon and includes cyclic hydrocarbon groups of from 3 to 8 carbon atoms. Examples of cycloalkyl groups include cy-propyl, cy-butyl, cypentyl, norbornyl and the like.
  • carbocycle is intended to include ring systems in which the ring atoms are all carbon but of any oxidation state.
  • C 3 -C 10 carbocycle refers to both non-aromatic and aromatic systems, including such systems as cyclopropane, benzene and cyclohexene;
  • C 8 -C 12 carbopolycycle refers to such systems as norbornane, decalin, indane and naphthalene.
  • Carbocycle if not otherwise limited, refers to monocycles, bicycles and polycycles.
  • Heterocycle means an aliphatic or aromatic carbocycle residue in which from one to four carbons is replaced by a heteroatom selected from the group consisting of N, O, and S.
  • the nitrogen and sulfur heteroatoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized.
  • a heterocycle may be non-aromatic (heteroaliphatic) or aromatic (heteroaryl).
  • heterocycles include pyrrolidine, pyrazole, pyrrole, indole, quinoline, isoquinoline, tetrahydroisoquinoline, benzofuran, benzodioxan, benzodioxole (commonly referred to as methylenedioxyphenyl, when occurring as a substituent), tetrazole, morpholine, thiazole, pyridine, pyridazine, pyrimidine, thiophene, furan, oxazole, oxazoline, isoxazole, dioxane, tetrahydrofuran and the like.
  • heterocyclyl residues include piperazinyl, piperidinyl, pyrazolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyrazinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, isothiazolyl, quinuclidinyl, isothiazolidinyl, benzimidazolyl, thiadiazolyl, benzopyranyl, benzothiazolyl, tetrahydrofuryl, tetrahydropyranyl, thienyl (also historically called thiophenyl), benzothienyl, thiamorpholinyl, oxadiazolyl, triazolyl and tetrahydroquinolinyl.
  • Alkoxy or alkoxyl refers to groups of from 1 to 20 carbon atoms, preferably 1 to 10 carbon atoms, more preferably 1 to 6 carbon atoms of a straight or branched configuration attached to the parent structure through an oxygen. Examples include methoxy, ethoxy, propoxy, isopropoxy and the like. Lower-alkoxy refers to groups containing one to four carbons. For the purpose of this application, alkoxy and lower alkoxy include methylenedioxy and ethylenedioxy.
  • halogen means fluorine, chlorine, bromine or iodine atoms. In one embodiment, halogen may be a fluorine or chlorine atom.
  • Oxaalkyl refers to alkyl residues in which one or more carbons (and their associated hydrogens) have been replaced by oxygen. Examples include methoxypropoxy, 3,6,9-trioxadecyl and the like.
  • the term oxaalkyl is intended as it is understood in the art [see Naming and Indexing of Chemical Substances for Chemical Abstracts, published by the American Chemical Society, 2002 editi on, ⁇ 196, but without the restriction of 127(a)], i.e. it refers to compounds in which the oxygen is bonded via a single bond to its adjacent atoms (forming ether bonds); it does not refer to doubly bonded oxygen, as would be found in carbonyl groups.
  • thiaalkyl and azaalkyl refer to alkyl residues in which one or more carbons has been replaced by sulfur or nitrogen, respectively.
  • Examples of azaalkyl include ethylaminoethyl and aminohexyl.
  • substituted refers to the replacement of one or more hydrogen atoms in a specified group with a specified radical.
  • R n are generally defined when introduced in a claim and retain that definition throughout the all the claims. Certain R n in the detailed description have definitions that are associated only with a particular set of exemplary syntheses; the R n in the exemplary syntheses do not necessarily correlate with the R n in the claims or summary of the invention.
  • a compound of formula I as depicted above may include a substituent NH 2 , such as in Example 05-25 below, and therefore would also include salts in which the substituent is NH 3 + X - , wherein X is any counterion.
  • the term "compound of formula I" refers to the compound or a pharmaceutically acceptable salt thereof.
  • Suitable pharmaceutically acceptable acids for salts of the amino-substituted compounds of the present invention include, for example, acetic, adipic, alginic, ascorbic, aspartic, benzenesulfonic (besylate), benzoic, boric, butyric, camphoric, camphorsulfonic, carbonic, citric, ethanedisulfonic, ethanesulfonic, ethylenediaminetetraacetic, formic, fumaric, glucoheptonic, gluconic, glutamic, hydrobromic, hydrochloric, hydroiodic, hydroxynaphthoic, isethionic, lactic, lactobionic, laurylsulfonic, maleic, malic, mandelic, methanesulfonic, mucic, naphthylenesulfonic,
  • Suitable pharmaceutically acceptable base addition salts for the carboxylate-substituted compounds of the present invention include, but are not limited to, metallic salts made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc or organic salts made from lysine, arginine, N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine), and procaine.
  • Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium cations and carboxylate, sulfonate and phosphonate anions attached to alkyl having from 1 to 20 carbon atoms.
  • the compounds of this invention can exist in radiolabeled form, i.e., the compounds may contain one or more atoms containing an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Alternatively, a plurality of molecules of a single structure may include at least one atom that occurs in an isotopic ratio that is different from the isotopic ratio found in nature.
  • Radioisotopes of hydrogen, carbon, phosphorous, fluorine, chlorine and iodine include 2 H, 3 H, 11 C, 13 C, 14 C, 15 N, 35 S, 18 F, 36 Cl, 125 I, 124 I, and 131 I respectively.
  • Radiolabeled compounds of formula I of this invention and prodrugs thereof can generally be prepared by methods well known to those skilled in the art. Conveniently, such radiolabeled compounds can be prepared by carrying out the procedures disclosed in the Examples and Schemes by substituting a readily available radiolabeled reagent for a non-radiolabeled reagent.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula I or a pharmaceutically acceptable salt or solvate thereof, together with one or more pharmaceutically carriers thereof and optionally one or more other therapeutic ingredients.
  • the carrier(s) must be "acceptable” in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
  • the compositions may be formulated for oral, topical, or parenteral administration. For example, they may be given intravenously, intraarterially, subcutaneously, and directly into the CNS - either intrathecally or intracerebroventricularly.
  • Formulations include those suitable for oral, parenteral (including subcutaneous, intradermal, intramuscular, intravenous, and intraarticular), rectal and topical (including dermal, buccal, sublingual, and intraocular) administration.
  • the compounds are preferably administered orally or by injection (intravenous or subcutaneous).
  • the precise amount of compound administered to a patient will be the responsibility of the attendant physician. However, the dose employed will depend on a number of factors, including the age and sex of the patient, the precise disorder being treated, and its severity. Also, the route of administration may vary depending on the condition and its severity.
  • the formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired formulation.
  • Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets, or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion.
  • the active ingredient may also be presented as a bolus, electuary, or paste.
  • the formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavoring agents.
  • treatment or “treating,” or “palliating” or “ameliorating” are used interchangeably herein. These terms refers to an approach for obtaining a therapeutic benefit in the form of eradication or amelioration of the underlying disorder being treated. Also, a therapeutic benefit is achieved with the eradication or amelioration of one or more of the physiological systems associated with the underlying disorder such that an improvement is observed in the patient, notwithstanding that the patient may still be afflicted with the underlying disorder.
  • the compositions may be administered to a patient at risk of developing a particular disease, or to a patient reporting one or more of the physiological systems of a disease, even though a diagnosis of this disease may not have been made.
  • a protecting group refers to a group, which is used to mask a functionality during a process step in which it would otherwise react, but in which reaction is undesirable.
  • the protecting group prevents reaction at that step, but may be subsequently removed to expose the original functionality. The removal or "deprotection” occurs after the completion of the reaction or reactions in which the functionality would interfere.
  • the compounds of the present invention may be prepared by the methods illustrated in the general reaction schemes as, for example, described below, or by modifications thereof, using readily available starting materials, reagents and conventional synthesis procedures. In these reactions, it is also possible to make use of variants that are in themselves known, but are not mentioned here.
  • the starting materials are either commercially available, synthesized as described in the examples or may be obtained by the methods well known to persons of skill in the art. Standard synthetic methods and procedures for the preparation of organic molecules and functional group transformations and manipulations can be readily obtained from the relevant scientific literature or from standard textbooks in the field.
  • Suitable solvents typically are substantially nonreactive with the reactants, intermediates, and/or products at the temperatures at which the reactions are carried out, i.e., temperatures that can range from the solvent's freezing temperature to the solvent's boiling temperature.
  • a given reaction can be carried out in one solvent or a mixture of more than one solvent.
  • suitable solvents for a particular reaction step can be selected.
  • NMR Nuclear Magnetic Resonance
  • 13 CNMR spectra were in relevant cases consistent with the proposed structures.
  • NMR were acquired on a Bruker® DRX-600 spectrometer at 600 MHz for 1 H and 125 MHz for 13 C.
  • Characteristic chemical shifts ( ⁇ ) are expressed in parts per million downfield from tetramethylsilane (TMS) using conventional abbreviations for designation of major peaks: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad.
  • TMS tetramethylsilane
  • the following abbreviations have been used for common solvents: CDCl 3 , deuterochloroform; D6-DMSO, deuterodimethyl-sulfoxide; MeOD, deuteromethanol.
  • Reagents used in the preparation of the compounds of this invention can be either obtained commercially or prepared by standard literature procedures. Unless otherwise stated, all reagents and solvents were obtained from commercial suppliers and used without further purification.
  • TLC thin layer chromatography
  • Schemes 1-4 present general synthetic approaches. The details of each example are described in the Examples. Compounds may be prepared according to the reactions in Scheme 1.
  • R 1 can be present from commercial reagents, added through C-alkylation, or formed through ring opening chemistry.
  • R 2 can be hydrogen, present from commercial reagents, or prepared as in Scheme 2, have appended acid, ester, nitro, or protected amine functionalities.
  • R 8 can be from reagents bearing a halogen.
  • Appended acid, or ester, compounds can undergo reactions in Scheme 2.
  • Compounds can be protected commercial reagents, or from Scheme 1.
  • R 3 can be added with an appended ester functionality and undergo a second iteration of base hydrolysis and amide bond formation.
  • R 5 can be from carboxylic acids, acid halides, anhydrides, cyclic anhydrides, or activated acids.
  • R 6 can be from sulfonic acids, or sulfonyl chlorides.
  • R 7 can be from aldehydes.
  • R 8 can be from reagents bearing a halogen.
  • Alkynes can undergo reactions in Scheme 4.
  • R 9 can be from azides or amines.
  • 1,3-Cyclopentandione (0.98 g, 10.0 mmol, 1.0 eq, Synth. Comm. 1993, 23(22), p. 3095-3108 ) was treated with 40% aq Triton B (3.95 mL ⁇ 1.0 eq) in DI H 2 O (5.0 mL) followed by benzyl bromide (1.4 mL, 1.2 eq). The reaction mixture was stirred at rt for 24 h. The crude was extracted with EtOAc and dried over anhyd sodium sulfate. The reaction on a 10.0 mmol scale yielded 0.9 g of the title intermediate after recrystallization from EtOAc (48% yield).
  • 1,3-Cyclopentandione (491 mg, 5.0 mmol, 1.0 eq, J. Org. Chem. 1988, 53, p. 891-893 ) was treated with AcOH (315 mL, 1.1 eq) followed by p -hydroxybenzyl alcohol (683 mg, 1.1 eq).
  • Microwave irradiation was applied to a sealed microwave vial for 10 min in a single mode Biotage®-Initiator cavity, producing continuous irradiation to hold 120°C at 2.45 GHz.
  • Step 1 N -Formylation: A mixture of formic acid (18.1 mL, 40 eq, Chem. Pharm. Bull. 2002, 50(7), p. 941-959 ) and acetic anhydride (11.3 mL, 10 eq) were heated to 50°C for 1 h. After addition of 4-amino-3-chlorobenzoic acid (2.1 g, 12.0 mmol, 1.0 eq), the whole was heated to 65°C for 2 h and cooled to rt. The reaction mixture was poured into cold H 2 O and the precipitates were collected by filtration, washed with H 2 O, and dried on the frit.
  • 4-amino-3-chlorobenzoic acid 2.1 g, 12.0 mmol, 1.0 eq
  • Step 2 IBCF Method C: 3-Chloro-4-formamidobenzoic acid and o -toluidine were coupled according to the procedure of Example 04-13; 5.0 mmol scale yielded 1.0 g of 3-chloro-4-formamido- N -( o -tolyl)benzamide from precipitate (69% yield).
  • N -Deformylation Acetyl chloride (14eq, Org. Lett. 2011, 13(12), p. 3028-3031 ) was added to a CH 2 Cl 2 :MeOH (20 mL, 1:1) mixture at 0°C, followed by the 3-chloro-4-formamido- N -( o -tolyl)benzamide (0.87 g, 3.0 mmol, 1.0 eq). After warming to rt, HCl salts were collected by filtration and dried on the frit.
  • Step 2 IBCF Method C: 3-Fluoro-4-formamidobenzoic acid and p -anisidine were coupled according to the procedure of Example 04-13; 5.0 mmol scale yielded 1.0 g of 3-fluoro-4-formamido- N -(4-methoxyphenyl)benzamide from precipitate (69% yield).
  • Step 3 N -Deformylation: The title intermediate was prepared from 3-fluoro-4-formamido- N -(4-methoxyphenyl)benzamide according to the procedure of Intermediate 03; 3.3 mmol scale, with solvent (20 mL), yielded 0.9g of 2-fluoro-4-((4-methoxyphenyl)carbamoyl)-benzenaminium chloride (92% yield).
  • Step 2 IBCF Method C: 3-Bromo-4-formamidobenzoic acid and p -anisidine were coupled according to the procedure of Example 04-13; 5.0 mmol scale (exothermic) yielded 0.27 g of 3-bromo-4-formamido- N -(4-methoxyphenyl)benzamide from precipitate (15% yield).
  • Step 3 N -Deformylation: The title intermediate was prepared from 3-bromo-4-formamido- N -(4-methoxyphenyl)benzamide according to the procedure of Intermediate 03; 0.75 mmol scale, with solvent (10 mL), yielded 0.16 g of 2-bromo-4-((4-methoxyphenyl)carbamoyl)-benzenaminium chloride (66% yield).
  • Step 1 1,3-Cyclohexandione (2.24 g, 20.0 mmol, J. Med. Chem. 2011, 54, p. 5070-5081 ) and 1,1-dimethyoxy- N , N -dimethylmethanamine (DMF-DMA, 26.5 mL, 200 mmol, 10 eq) were mixed and heated under reflux for 3h. The solvent was removed on the rotovap to provide the product in suitable purity for the next step. The reaction on a 20.0 mmol scale yielded 3.25 g of 2-((dimethylamino)methylene)-cyclohexane-1,3-dione (97% yield).
  • DMF-DMA 1,1-dimethyoxy- N , N -dimethylmethanamine
  • 1 H NMR (D6-DMSO) ⁇ 1.85-1.91 (m, 2H), 2.44-2.50 (m, 4H).
  • 6-Amino-5-chloro-2-naphthoic acid 6-Amino-2-naphthoic acid (0.17 g, 0.9 mmol), N-chlorosuccinimide (0.12 g, 1 eq), and carbon tetrachloride (25 mL) were combined in a round bottom flask, and heated under reflux for 1h. After cooling to rt, the solid was filtered. The subsequent crude materials were added directly to KP-SilTM columns (10 g) with products separating from impurities using an isocratic solvent system CH 2 Cl 2 :MeOH (1:19), on the Biotage®-Isolera Four instrument, monitoring UV Trace at 254/365 nm.
  • IsoluteTM HM-N was added to the crude solution and dried on the rotovap.
  • the crude material absorbed to IsoluteTM was packed into an empty samplet (1 g) and placed into the receiving KP-SilTM column (10 g).
  • Products were separated from impurities using an isocratic solvent system, EtOAc:acetone (17:3), on Biotage®-Isolera Four instrument, monitoring UV Trace at 254/365 nm.
  • the reaction on a 0.5 mmol scale yielded 15 mg of the title compound (10% yield).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Claims (16)

  1. Verbindung der Formel 1 oder pharmazeutisch annehmbares Salz davon:
    Figure imgb0192
     wobei:
    U = (CH2)n ist, wobei n = 1, 2 oder 3 ist;
    R1 aus der Gruppe ausgewählt ist, die aus (C1-C10)-Alkyl, mit einem oder mehreren Fluoratomen substituiertem (C1-C10)-Alkyl und Nitril besteht;
    Cy aus der Gruppe ausgewählt ist, die aus Phenyl, Naphthyl, Indol, Chinolin, Isochinolin, Pyridin und Benzimidazolyl besteht;
    R11 und R12 unabhängig aus der Gruppe ausgewählt sind, die aus H, (C1-C10)-Alkyl, (C1-C10)-Perfluoralkyl, Halogen, Hydroxy, (C1-C10)-Alkoxy, Amino, (C1-C10)-Alkylamino, (C1-C10)-Acylamino, Aryl, Heteroaryl, Aminocarbonyl, Carboxy und (C1-C10)-Alkoxycarbonyl besteht, oder R11 und R12 zusammen genommen einen fünf-, sechs- oder siebengliedrigen Carbocyclus oder Heterocyclus bilden können, wobei der Carbocyclus oder Heterocyclus gegebenenfalls mit R2 substituiert sein kann;
    R2 aus der Gruppe ausgewählt ist, die aus Halogen, (C1-C4)-Alkyl, Halogen-(C1-C4)-alkyl, Hydroxy, (C1-C4)-Alkoxy, Halogen-(C1-C4)-alkoxy, Carboxy, Amino, (C1-C4)-Alkylamino und Di(C1-C4)alkylamino besteht;
    Y aus
    Figure imgb0193
    Figure imgb0194
    Figure imgb0195
    Figure imgb0196
    Figure imgb0197
    Figure imgb0198
    Figure imgb0199
    Figure imgb0200
    Figure imgb0201
     ausgewählt ist;
    L und L' unabhängig eine Bindung oder (CR3R4)m sind, wobei R3 und R4 unabhängig aus der Gruppe ausgewählt sind, die aus H und (C1-C4)-Alkyl besteht, und m = 1 oder 2 ist;
    R10 aus Carbocyclus und Heterocyclus ausgewählt ist, wobei der Carbocyclus oder Heterocyclus gegebenenfalls mit R7 und/oder R8 substituiert ist;
    R20 = -C(=O)OR21 ist;
    R21 aus H und (C1-C4)-Alkyl ausgewählt ist;
    R5 und R6 unabhängig aus der Gruppe ausgewählt sind, die aus Wasserstoff, Hydroxy, (C1-C10)-Hydrocarbyl, Halogen(C1-C10)hydrocarbyl und (C1-C10)-Alkoxy besteht;
    R7 und R8 unabhängig aus der Gruppe ausgewählt sind, die aus Hydroxy, Halogen, (C1-C4)-Alkyl, Halogen(C1-C4)alkyl, Hydroxy(C1-C4)alkyl, (C1-C4)-Alkoxy, Halogen(C1-C4)alkoxy, (C1-C4)-Alkylthio, (C1-C4)-Alkylcarbonyl, Aryl, Heteroaryl, Cycloalkyl, Heterocycloalkyl, Cyano, Oxo, (C1-C4)-Alkylsulfonyl, Amino, (C1-C4)-Alkylamino, Di(C1-C4)alkylamino, (C1-C4)-Acylamino, Aminocarbonyl, Carboxy und (C1-C4)-Alkoxycarbonyl besteht, wobei jedes Alkyl, Aryl, Heteroaryl, Cycloalkyl oder Heterocycloalkyl weiterhin gegebenenfalls mit Hydroxy, Oxo, Carboxy, Carboxy(C1-C4)alkyl, Hydroxy(C1-C4)alkyl, (C1-C4)-Alkoxy, (C1-C4)-Alkoxycarbonyl, (C1-C4)-Alkoxycarbonyl(C1-C4)alkyl, Amino, (C1-C4)-Alkylamino, Di(C1-C4)alkylamino, Amido, (C1-C4)-Alkylamido, Di(C1-C4)alkylamido, Halogen, (C1-C4)-Alkyl, Halogen(C1-C4)alkyl, Aryl, Heteroaryl, Heterocycloalkyl oder Cycloalkyl substituiert sein kann;
    oder R5 und R6 oder R7 und R8 zusammen genommen einen fünf-, sechs- oder siebengliedrigen Carbocyclus oder Heterocyclus bilden können, wobei der Carbocyclus oder Heterocyclus gegebenenfalls mit R9 substituiert ist;
    R9 aus der Gruppe ausgewählt ist, die aus Halogen, (C1-C4)-Alkyl, Halogen-(C1-C4)alkyl, Hydroxy, (C1-C4)-Alkoxy, Halogen(C1-C4)alkoxy, Amino, (C1-C4)-Alkylamino und Di(C1-C4)alkylamino besteht.
  2. Verbindung gemäß Anspruch 1 oder pharmazeutisch annehmbares Salz davon, wobei Cy Phenyl oder Naphthyl ist, gegebenenfalls Phenyl die folgende Formel aufweist:
    Figure imgb0202
  3. Verbindung gemäß einem der Ansprüche 1 bis 2 oder pharmazeutisch annehmbares Salz davon, wobei Y Folgendes ist:
    Figure imgb0203
  4. Verbindung gemäß Anspruch 3 oder pharmazeutisch annehmbares Salz davon, wobei L = -CH2- ist und gegebenenfalls R10 aus Cyclohexyl, Cyclopentyl, Phenyl, Naphthyl, Thiophenyl, Pyrrolyl, Pyridinyl und Pyrimidinyl ausgewählt ist, das jeweils gegebenenfalls mit R7 und/oder R8 substituiert ist.
  5. Verbindung gemäß Anspruch 2 oder pharmazeutisch annehmbares Salz davon, wobei Y aus
    Figure imgb0204
     ausgewählt ist;
    L eine direkte Bindung ist;
    L' eine direkte Bindung oder CH2 ist; und
    R21 = H ist.
  6. Verbindung gemäß Anspruch 1 oder pharmazeutisch annehmbares Salz davon, wobei Y =
    Figure imgb0205
    Figure imgb0206
     ist.
  7. Verbindung gemäß einem der Ansprüche 1 bis 3 oder 5 oder pharmazeutisch annehmbares Salz davon, wobei
    R21 Wasserstoff oder Methyl ist; oder
    R11 Wasserstoff ist und R12 Halogen ist.
  8. Verbindung gemäß einem der Ansprüche 1 bis 2 oder pharmazeutisch annehmbares Salz davon, wobei U = -CH2CH2- oder -CH2- ist.
  9. Verbindung gemäß einem der vorstehenden Ansprüche oder pharmazeutisch annehmbares Salz davon, wobei R10 =
    Figure imgb0207
     ist.
  10. Verbindung gemäß einem der vorstehenden Ansprüche oder pharmazeutisch annehmbares Salz davon, wobei R7 aus Halogen, (C1-C4)-Alkyl, Halogen(C1-C4)alkyl, (C1-C4)-Alkoxy, Halogen(C1-C4)alkoxy und Aminocarbonyl ausgewählt ist.
  11. Verbindung gemäß Anspruch 1 oder pharmazeutisch annehmbares Salz davon, ausgewählt aus:
    3-Chlor-4-((2-methyl-3-oxocyclopent-1-en-1-yl)amino)-N-(naphthalen-1-yl)benzamid (Bsp. 04-15),
    3-Chlor-N-(2-methoxyphenyl)-4-((2-methyl-3-oxocyclopent-1-en-1-yl)-amino)benzamid (Bsp. 04-17),
    3-Chlor-N-(3-methoxyphenyl)-4-((2-methyl-3-oxocyclopent-1-en-1-yl)-amino)benzamid (Bsp. 04-18),
    3-Chlor-N-(4-methoxyphenyl)-4-((2-methyl-3-oxocyclopent-1-en-1-yl)-amino)benzamid (Bsp. 04-19),
    3-Chlor-4-((2-methyl-3-oxocyclopent-1-en-1-yl)amino)-N-(o-tolyl)benzamid (Bsp. 04-20),
    3-Chlor-4-(((2-methyl-3-oxocyclopent-1-en-1-yl)amino)-N-(m-tolyl)benzamid (Bsp. 04-21),
    2-Methoxy-4-((2-methyl-3-oxocyclopent-1-en-1-yl)amino)-N-(naphthalen-1-yl)benzamid (Bsp. 04-67),
    2-Methoxy-N-(2-methoxyphenyl)-4-((2-methyl-3-oxocyclopent-1-en-1-yl)-amino)benzamid (Bsp. 04-69),
    2-Methoxy-4-((2-methyl-3-oxocyclopent-1-en-1-yl)amino)-N-(o-tolyl)-benzamid (Bsp. 04-72),
    3-Chlor-N-(4-methoxyphenyl)-4-((2-methyl-3-oxocyclohex-1-en-1-yl)-amino)benzamid (Bsp. 5-13),
    3-Chlor-N-(2-methoxyphenyl)-4-((2-methyl-3-oxocyclohex-1-en-1-yl)-amino)benzamid (Bsp. 05-14),
    3-Chlor-4-((2-methyl-3-oxocyclohex-1-en-1-yl)amino)-N-(o-tolyl)benzamid (Bsp. 05-15),
    N-(4-Chlor-3-((2-methyl-3-oxocyclopent-1-en-1-yl)amino)phenyl)-4-methoxybenzamid (Bsp. 05-37),
    N-(4-Chlor-3-((2-methyl-3-oxocyclopent-1-en-1-yl)amino)phenyl)-2-methylbenzamid (Bsp. 05-38),
    N-(3-Chlor-4-((2-methyl-3-oxocyclopent-1-en-1-yl)amino)phenyl)-2-methylbenzamid (Bsp. 05-41),
    N-(2-Chlor-3-((2-methyl-3-oxocyclopent-1-en-1-yl)amino)phenyl)-2-methylbenzamid (Bsp. 05-42),
    N-(4-Chlor-3-((2-methyl-3-oxocyclohex-1-en-1-yl)amino)phenyl)-4-methoxybenzamid (Bsp. 05-43),
    N-(4-Chlor-3-((2-methyl-3-oxocyclohex-1-en-1-yl)amino)phenyl)-2-methylbenzamid (Bsp. 05-44),
    N-(4-Chlor-3-((2-methyl-3-oxocyclopent-1-en-1-yl)amino)phenyl)-1-phenylmethansulfonamid (Bsp. 05-54),
    N-(4-Chlor-3-((2-methyl-3-oxocyclopent-1-en-1-yl)amino)phenyl)-2-chlor-benzolsulfonamid (Bsp. 05-56),
    N-(4-Chlor-3-((2-methyl-3-oxocyclopent-1-en-1-yl)amino)phenyl)-2-methylbenzolsulfonamid (Bsp. 05-57),
    N-(4-Chlor-3((2-methyl-3-oxocyclopent-1-en-1-yl)amino)phenyl)-2-fluor-benzolsulfonamid (Bsp. 05-58),
    N-(4-Chlor-3-((2-methyl-3-oxocyclopent-1-en-1-yl)amino)phenyl)-2-cyanobenzolsulfonamid (Bsp. 05-59),
    N-(4-Chlor-3-((2-methyl-3-oxocyclopent-1-en-1-yl)amino)phenyl)-2-methoxybenzolsulfonamid (Bsp. 05-60),
    N-(4-Chlor-3-((2-methyl-3-oxocyclopent-1-en-1-yl)amino)phenyl)piperidin-1-sulfonamid (Bsp. 05-61),
    N-(4-Chlor-3-((2-methyl-3-oxocyclopent-1-en-1-yl)amino)phenyl)morpholin-4-sulfonamid (Bsp. 05-62),
    N-(3-Chlor-4-((2-methyl-3-oxocyclopent-1-en-1-yl)amino)phenyl)cyclohexansulfonamid (Bsp. 05-64),
    N-(2-Chlor-3-((2-methyl-3-oxocyclopent-1-en-1-yl)amino)phenyl)-2-methylbenzolsulfonamid (Bsp. 05-65),
    N-(4-Chlor-3-((2-methyl-3-oxocyclohex-1-en-1-yl)amino)phenyl)-2-methylbenzolsulfonamid (Bsp. 05-66),
    N-(4-Chlor-3-((2-methyl-3-oxocyclohex-1-en-1-yl)amino)phenyl)cyclo-hexansulfonamid (Bsp. 05-67),
    N-(3-Chlor-4-((2-methyl-3-oxocyclohex-1-en-1-yl)amino)phenyl)-2-methylbenzolsulfonamid (Bsp. 05-68),
    N-(2-Chlor-3-((2-methyl-3-oxocyclohex-1-en-1-yl)amino)phenyl)-2-methylbenzolsulfonamid (Bsp. 05-70),
    3-((2-Chlor-5-((2-methylbenzyl)amino)phenyl)amino)-2-methylcyclohex-2-enon (Bsp. 05-72) und
    3-((2-Chlor-5-((2-fluorbenzyl)amino)phenyl)amino)-2-methylcyclohex-2-enon (Bsp. 05-74).
  12. Pharmazeutische Zusammensetzung, die einen pharmazeutisch annehmbaren Träger und eine Verbindung gemäß einem der Ansprüche 1 bis 11 oder ein pharmazeutisch annehmbares Salz davon umfasst.
  13. Verbindung gemäß einem der Ansprüche 1 bis 11 oder pharmazeutisch annehmbares Salz davon zur Verwendung bei der Behandlung einer Erkrankung oder Störung, die aus der Gruppe ausgewählt ist, welche aus chronischer Entzündung, Autoimmunerkrankung und Krebs besteht.
  14. Verbindung zur Verwendung gemäß Anspruch 13, wobei die Behandlung einer Erkrankung oder Störung weiterhin das Verabreichen einer zusätzlichen therapeutischen Mittels umfasst.
  15. Verwendung einer Verbindung gemäß einem der Ansprüche 1 bis 11 oder eines pharmazeutisch annehmbaren Salzes davon zur Hemmung einer Bromodomäne in vitro in einer Zelle, umfassend das In-Kontakt-Bringen der Zelle mit einer hemmenden Menge einer Verbindung gemäß einem der Ansprüche 1 bis 11.
  16. Verbindung gemäß einem der Ansprüche 1 bis 11 oder pharmazeutisch annehmbares Salz davon zur Verwendung in der Therapie.
EP14839424.0A 2013-08-30 2014-08-29 Cyclische vinylogenamide als bromdomänenhemmer Active EP3038612B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361872303P 2013-08-30 2013-08-30
PCT/US2014/053527 WO2015031824A1 (en) 2013-08-30 2014-08-29 Cyclic vinylogous amides as bromodomain inhibitors

Publications (3)

Publication Number Publication Date
EP3038612A1 EP3038612A1 (de) 2016-07-06
EP3038612A4 EP3038612A4 (de) 2017-01-11
EP3038612B1 true EP3038612B1 (de) 2020-07-29

Family

ID=52587390

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14839424.0A Active EP3038612B1 (de) 2013-08-30 2014-08-29 Cyclische vinylogenamide als bromdomänenhemmer

Country Status (4)

Country Link
US (2) US9884806B2 (de)
EP (1) EP3038612B1 (de)
CN (1) CN105873577B (de)
WO (1) WO2015031824A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201504694D0 (en) 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Covalent conjugates
US10702517B2 (en) 2015-04-22 2020-07-07 Celgene Quanticel Research, Inc. Bromodomain inhibitor
CN106279141B (zh) * 2015-06-11 2021-02-12 华东理工大学 检测二氢乳清酸脱氢酶的化合物
EP3528810A4 (de) * 2016-10-20 2020-06-17 Celgene Quanticel Research, Inc. Bromdomäneninhibitor
CN110636846B (zh) 2017-05-17 2023-05-16 艾库斯生物科学有限公司 用于治疗癌症相关疾病的喹唑啉吡唑衍生物
CN109796360B (zh) * 2019-01-30 2022-03-18 上海阿拉丁生化科技股份有限公司 一种3-氨基-2-萘甲酸类化合物的制备工艺
IL294052A (en) 2019-12-20 2022-08-01 Tenaya Therapeutics Inc Fluoroalkyl-oxadiazoles and uses thereof
EP4333841A1 (de) 2021-05-04 2024-03-13 Tenaya Therapeutics, Inc. 2-fluoralkyl-1,3,4-oxadiazol-5-yl-thiazol-, hdac6-inhibitoren zur verwendung bei der behandlung von stoffwechselerkrankungen und hfpef

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4338466A (en) * 1981-04-02 1982-07-06 The United States Of America As Represented By The Secretary Of The Navy Prostaglandin analogs and process of preparation thereof
JP2717687B2 (ja) * 1988-02-13 1998-02-18 日本曹達株式会社 ピリダジノン誘導体及びその製造方法
US6235736B1 (en) * 1997-06-24 2001-05-22 Nikken Chemicals Co., Ltd. 3-anilino-2-cycloalkenone derivatives
DE10254853A1 (de) 2002-11-25 2004-06-03 Basf Ag Verbessertes Verfahren zur Herstellung von Cyclopentenonen
US20090035784A1 (en) * 2004-07-30 2009-02-05 Mount Sinai School Of Medicine Of New York University Npc1l1 and npc1l1 inhibitors and methods of use thereof
US20100119525A1 (en) * 2005-08-01 2010-05-13 Mount Sinai Schoool Of Medicine Of New York University Method for extending longevity using npc1l1 antagonists
US20080269348A1 (en) * 2006-11-07 2008-10-30 Phil Skolnick Novel Arylbicyclo[3.1.0]Hexylamines And Methods And Compositions For Their Preparation And Use
WO2013027168A1 (en) 2011-08-22 2013-02-28 Pfizer Inc. Novel heterocyclic compounds as bromodomain inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
WO2015031824A9 (en) 2016-06-16
EP3038612A1 (de) 2016-07-06
EP3038612A4 (de) 2017-01-11
US20180105485A1 (en) 2018-04-19
CN105873577A (zh) 2016-08-17
US9884806B2 (en) 2018-02-06
US20160200666A1 (en) 2016-07-14
WO2015031824A1 (en) 2015-03-05
US10351511B2 (en) 2019-07-16
CN105873577B (zh) 2019-06-18

Similar Documents

Publication Publication Date Title
EP3038612B1 (de) Cyclische vinylogenamide als bromdomänenhemmer
JP6046154B2 (ja) Ｌｓｄ１阻害剤としての（ヘテロ）アリールシクロプロピルアミン化合物
DE69418704T2 (de) Anthranilsäure derivate
JP3953096B2 (ja) サイクリックａｍｐホスホジエステラーゼおよびｔｎｆ阻害剤としての置換芳香族化合物
TWI403319B (zh) 前列腺素ｄ2受體之雜烷基拮抗劑
DE60033689T2 (de) Inhibitoren von serinproteasen
JP2001525392A (ja) アダマンタン誘導体
EP3303293B1 (de) Ror-gamma modulatoren
JP2001526255A (ja) 炎症性疾患およびアテローム性動脈硬化症を治療または予防するチオ尿素およびベンズアミド化合物、組成物並びに方法
JP2002501945A (ja) Ｐｐａｒ−ガンマ調節剤
MXPA06002551A (es) Compuestos de aril o heteroaril amida.
WO2000077027A2 (en) Serine protease inhibitors
SK282721B6 (sk) Nepeptidové NK3 antagonistické látky, spôsob ich výroby, farmaceutické prostriedky s ich obsahom a ich použitie
JP2007261945A (ja) チアゾール誘導体
JP2006528971A (ja) 新規のベンゾイミダゾール誘導体
CN102639487A (zh) 治疗性芳基-酰氨基-芳基化合物以及它们的应用
AU2010311466B2 (en) 2-aryl-propionamide derivatives useful as bradykinin receptor antagonists and pharmaceutical compositions containing them
BR112013032306B1 (pt) derivados de indanona, método de preparação dos mesmos, composições farmacêuticas e uso dos mesmos para prevenção ou tratamento de doenças virais
US5866612A (en) Acetamidine derivatives and their use as inhibitors for the nitric oxide synthase
AU2008327709B2 (en) Inhibitors of 17beta-hydroxysteroid dehydrogenase
ES2907746T3 (es) Compuestos de amida y uso de los mismos
TWI396543B (zh) 取代丙烯醯胺衍生物及含有它之醫藥組成物
WO2019170050A1 (zh) 一种2-硫甲基吡唑嘧啶酮类化合物、其制备方法、药物组合物及应用
US20030119876A1 (en) Compounds for the treatment of protozoal diseases
JP2010526045A (ja) Ｃｄｃ２５ホスファターゼインヒビターとしてのトリアミノピリミジン誘導体

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20160316

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: OHLMEYER, MICHAEL

Inventor name: ZAWARE, NILESH

Inventor name: VINCEK, ADAM

Inventor name: ZHOU, MING-MING

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602014068382

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: A61K0031122000

Ipc: C07D0213750000

A4 Supplementary search report drawn up and despatched

Effective date: 20161214

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 249/06 20060101ALI20161208BHEP

Ipc: A61P 37/00 20060101ALI20161208BHEP

Ipc: C07D 215/38 20060101ALI20161208BHEP

Ipc: C07D 213/75 20060101AFI20161208BHEP

Ipc: A61P 35/00 20060101ALI20161208BHEP

Ipc: C07D 209/40 20060101ALI20161208BHEP

Ipc: C07D 213/76 20060101ALI20161208BHEP

Ipc: A61K 31/122 20060101ALI20161208BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20171222

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20200219

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1295620

Country of ref document: AT

Kind code of ref document: T

Effective date: 20200815

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602014068382

Country of ref document: DE

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20200729

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1295620

Country of ref document: AT

Kind code of ref document: T

Effective date: 20200729

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201029

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200729

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200729

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200729

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201029

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201130

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200729

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200729

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200729

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201030

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200729

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200729

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200729

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201129

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602014068382

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200729

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200729

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200831

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200729

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200729

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200729

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200729

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200729

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200829

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200831

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200729

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20200831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200729

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200729

26N No opposition filed

Effective date: 20210430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210302

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200929

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200829

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200729

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200729

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200729

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200729

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200729

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240827

Year of fee payment: 11